M&A Advisory
K&L Gates
Full Credential Description
Sentiss Pharma faced a significant challenge in acquiring Akorn AG Switzerland, which included navigating a complex bankruptcy auction process. This acquisition was crucial for Sentiss as it aimed to restore the supply of several essential pharmaceutical products, particularly those beneficial for US patients, including children with significant respiratory issues. K&L Gates LLP provided a tailored solution by advising Sentiss Pharma throughout the acquisition process. The firm’s team, led by partners Jonathan Barron and Lee Hogewood, along with associate Arielle Wisotsky, facilitated the acquisition of Akorn AG's US FDA-approved sterile manufacturing plant and its diverse of approved products. This strategic move not only expanded Sentiss Pharma's capabilities but also enhanced its global market presence by integrating a line of high-demand products and abbreviated new drug applications (ANDAs) that complemented its existing offerings. As a result of this acquisition, Sentiss Pharma was positioned to restore critical product supplies, thereby benefiting numerous patients in the US. This outcome underscores the importance of the acquisition in addressing urgent healthcare needs, particularly for vulnerable populations.